SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Inari Medical, Inc. (NARI) and Encourages Investors with Losses to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - March 18, 2024) - Kaskela Law LLC announces that it is investigating Inari Medical, Inc. (NASDAQ: NARI) ("Inari") on behalf of the company's shareholders.

Since January 2024, shares of Inari's common stock have declined in value from a trading price of over $65.00 per share to a current trading price of approximately $41.00 per share, a decline of over $24.00 per share, or approximately 37% in value.

The investigation seeks to determine whether Inari and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's shareholders.

Inari shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 - 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/inari-medical/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 - 1740
(484) 229 - 0750
www.kaskelalaw.com

This notice may constitute attorney advertising in certain jurisdictions.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/202074